Jade Biosciences annual free cash flow
2021
2022
2023
2025
Jade Biosciences reported −$94.9M in free cash flow for fiscal 2025, a decrease of $38.0M from the previous fiscal year.
View full Jade Biosciences company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$94.9M | −$38.0M | — | — |
| 2023 | 2023-12-31 | −$56.9M | −$17.6M | — | — |
| 2022 | 2022-12-31 | −$39.3M | −$11.7M | — | — |
| 2021 | 2021-12-31 | −$27.6M | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$22.2M | −$10.7M | — | — |
| Q4 2023 | 2023-12-31 | −$14.9M | $5,000 | — | — |
| Q3 2023 | 2023-09-30 | −$15.6M | −$5.9M | — | — |
| Q2 2023 | 2023-06-30 | −$15.0M | −$6.0M | — | — |
| Q1 2023 | 2023-03-31 | −$11.4M | −$5.8M | — | — |
| Q4 2022 | 2022-12-31 | −$14.9M | −$1.7M | — | — |
| Q3 2022 | 2022-09-30 | −$9.8M | −$3.2M | — | — |
| Q2 2022 | 2022-06-30 | −$9.0M | −$5.0M | — | — |
| Q1 2022 | 2022-03-31 | −$5.7M | −$1.9M | — | — |
| Q4 2021 | 2021-12-31 | −$13.2M | — | — | — |
| Q3 2021 | 2021-09-30 | −$6.6M | — | — | — |
| Q2 2021 | 2021-06-30 | −$4.0M | — | — | — |
| Q1 2021 | 2021-03-31 | −$3.8M | — | — | — |
Jade Biosciences's latest reported quarter, Q3 2025, generated −$22.2M in free cash flow, a decrease of $10.7M year over year.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Jade Biosciences filings at SEC.gov ↗